125 related articles for article (PubMed ID: 20955822)
1. Solid cancer, antiphospholipid antibodies, and venous thromboembolism.
Font C; Vidal L; Espinosa G; Tàssies D; Monteagudo J; Farrús B; Visa L; Cervera R; Gascon P; Reverter JC
Autoimmun Rev; 2011 Feb; 10(4):222-7. PubMed ID: 20955822
[TBL] [Abstract][Full Text] [Related]
2. A cross sectional study of antiphospholipid-protein antibodies in patients with venous thromboembolism.
Pasquier E; Amiral J; de Saint Martin L; Mottier D
Thromb Haemost; 2001 Aug; 86(2):538-42. PubMed ID: 11522000
[TBL] [Abstract][Full Text] [Related]
3. High factor VIII levels independently predict venous thromboembolism in cancer patients: the cancer and thrombosis study.
Vormittag R; Simanek R; Ay C; Dunkler D; Quehenberger P; Marosi C; Zielinski C; Pabinger I
Arterioscler Thromb Vasc Biol; 2009 Dec; 29(12):2176-81. PubMed ID: 19778945
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of antiphospholipid antibodies in Syrian patients with thrombosis.
Deeb A; Hamdoun S; Dababo K
Iran J Immunol; 2009 Sep; 6(3):154-9. PubMed ID: 19801789
[TBL] [Abstract][Full Text] [Related]
5. Treatment of venous thromboembolism in patients with cancer: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET).
Imberti D; Di Nisio M; Donati MB; Falanga A; Ghirarduzzi A; Guarneri D; Piovella F; Santoro RC; Baldini E; Zampogna S;
Thromb Res; 2009 Nov; 124(5):e32-40. PubMed ID: 19744700
[TBL] [Abstract][Full Text] [Related]
6. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study.
Ay C; Vormittag R; Dunkler D; Simanek R; Chiriac AL; Drach J; Quehenberger P; Wagner O; Zielinski C; Pabinger I
J Clin Oncol; 2009 Sep; 27(25):4124-9. PubMed ID: 19636003
[TBL] [Abstract][Full Text] [Related]
7. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients.
Khorana AA; Francis CW; Culakova E; Kuderer NM; Lyman GH
Cancer; 2007 Nov; 110(10):2339-46. PubMed ID: 17918266
[TBL] [Abstract][Full Text] [Related]
8. Impact of antiphospholipid antibodies on thrombotic events in ambulatory cancer patients.
Kansuttiviwat C; Niprapan P; Tantiworawit A; Norasetthada L; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Piriyakhuntorn P; Punnachet T; Hantrakun N; Chai-Adisaksopha C
PLoS One; 2023; 18(1):e0279450. PubMed ID: 36662720
[TBL] [Abstract][Full Text] [Related]
9. Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism.
Campello E; Spiezia L; Radu CM; Bulato C; Castelli M; Gavasso S; Simioni P
Thromb Res; 2011 May; 127(5):473-7. PubMed ID: 21256535
[TBL] [Abstract][Full Text] [Related]
10. Venous thromboembolism in patients with pancreatic cancer: implications of circulating tissue factor.
Delluc A; Rousseau A; Delluc C; Le Moigne E; Le Gal G; Mottier D; Van Dreden P; Lacut K
Blood Coagul Fibrinolysis; 2011 Jun; 22(4):295-300. PubMed ID: 21372691
[TBL] [Abstract][Full Text] [Related]
11. Antiphospholipid antibodies and malignancies.
Tincani A; Taraborelli M; Cattaneo R
Autoimmun Rev; 2010 Feb; 9(4):200-2. PubMed ID: 19386286
[TBL] [Abstract][Full Text] [Related]
12. Laboratory evaluation of antiphospholipid antibodies in patients with venous thromboembolism.
Hirmerova J; Ulcova-Gallova Z; Seidlerova J; Filipovsky J; Bibkova K; Micanova Z; Mayer O
Clin Appl Thromb Hemost; 2010 Jun; 16(3):318-25. PubMed ID: 19221100
[TBL] [Abstract][Full Text] [Related]
13. The association between ABO blood types and venous thromboembolism in individuals with a positive antiphospholipid profile is varied by sex.
Shusterman M; Golub E; Mowrey WB; Broder A
Lupus; 2018 Feb; 27(2):319-326. PubMed ID: 28705035
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: the M. D. Anderson Cancer Center experience.
Vemulapalli S; Chintala L; Tsimberidou AM; Dhillon N; Lei X; Hong D; Kurzrock R
Am J Hematol; 2009 Jul; 84(7):408-13. PubMed ID: 19437507
[TBL] [Abstract][Full Text] [Related]
15. Anti-prothrombin antibodies as a potential risk factor of recurrent venous thromboembolism.
Zanon E; Saggiorato G; Ramon R; Girolami A; Pagnan A; Prandoni P
Thromb Haemost; 2004 Feb; 91(2):255-8. PubMed ID: 14961151
[TBL] [Abstract][Full Text] [Related]
16. Retrospective evaluation of venous thromboembolism prophylaxis in the adult cancer population.
Reeves D; Liu CY
J Oncol Pharm Pract; 2010 Mar; 16(1):27-31. PubMed ID: 19401307
[TBL] [Abstract][Full Text] [Related]
17. Antiphospholipid antibodies and antiphospholipid syndrome in patients with malignancies: features, incidence, identification, and treatment.
Miesbach W
Semin Thromb Hemost; 2008 Apr; 34(3):282-5. PubMed ID: 18720308
[TBL] [Abstract][Full Text] [Related]
18. Impact of high titre of antiphospholipid antibodies on postoperative outcome following pulmonary endarterectomy.
D'Armini AM; Totaro P; Nicolardi S; Morsolini M; Silvaggio G; Toscano F; Toscano M; Viganò M
Interact Cardiovasc Thorac Surg; 2010 Mar; 10(3):418-22. PubMed ID: 19934162
[TBL] [Abstract][Full Text] [Related]
19. Elevated white blood cell count and outcome in cancer patients with venous thromboembolism. Findings from the RIETE Registry.
Trujillo-Santos J; Di Micco P; Iannuzzo M; Lecumberri R; Guijarro R; Madridano O; Monreal M;
Thromb Haemost; 2008 Nov; 100(5):905-11. PubMed ID: 18989537
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies.
Tektonidou MG; Laskari K; Panagiotakos DB; Moutsopoulos HM
Arthritis Rheum; 2009 Jan; 61(1):29-36. PubMed ID: 19116963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
